Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   11/12/2024
1,506 CHF (+12,64%)
(+12,64%)   11/12/2024

27 november 2024 · Idorsia enters into exclusive negotiations for global rights to aprocitentan · Persbericht

11 november 2024 · Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions · Persbericht

29 oktober 2024 · Idorsia announces financial results for the first nine months of 2024 · Persbericht

16 oktober 2024 · New data on aprocitentan to be presented at the ASN Kidney Week 2024 · Persbericht

17 september 2024 · Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 · Persbericht

5 september 2024 · New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 · Persbericht

2 september 2024 · Amended terms of Idorsia’s 2024 convertible bonds become effective · Persbericht

25 juli 2024 · Idorsia announces financial results for the first half 2024 · Persbericht

18 juli 2024 · Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call · Persbericht

1 juli 2024 · Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension · Persbericht

28 juni 2024 · Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds · Persbericht

25 juni 2024 · Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds · Persbericht

21 juni 2024 · Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category · Persbericht

13 juni 2024 · Idorsia holds its Annual General Meeting of Shareholders · Persbericht

3 juni 2024 · New data with daridorexant to be presented at SLEEP 2024 · Persbericht

31 mei 2024 · Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 · Persbericht

23 mei 2024 · Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders · Persbericht

21 mei 2024 · Idorsia announces changes to Idorsia Executive Committee and Board of Directors · Persbericht

21 mei 2024 · Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor · Persbericht

21 mei 2024 · Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value · Persbericht

Mijn selecties